AI Article Synopsis

  • * About 30% of patients with early-stage MF or SS will see their disease get worse within ten years, especially if they have certain risk factors like age over 60.
  • * Treatment can help, but there's no cure for advanced stages, and patients often have a lower quality of life; newer medicines like Brentuximab Vedotin and mogamulizumab are showing promise for improving survival.

Article Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most prevalent non-Hodgkin lymphomas that comprise cutaneous T-cell lymphomas (CTCL), accounting for more than 70% of cases. Following the Tumor Lymph nodes Metastasis Blood system, disease staging is carried out, and within ten years, about thirty percent of patients in the early stages will have advanced disease. Plaques, folliculotropism, and age over 60 are risk factors for progression. A 5-year survival rate of less than 20% is associated with LCT in MF. Treatment requires an interdisciplinary approach; skin-directed therapies are available for early stages of the disease, but there are no curative options for advanced stages of the disease other than allogeneic stem cell transplantation. Because of their severe symptoms and poor treatment efficacy, patients in advanced stages have a lower quality of life and a lower chance of survival. In patients with CD30-expressing CTCL, Brentuximab Vedotin has demonstrated better response rates and progression-free survival (PFS); in advanced SS, mogamulizumab has significantly increased PFS. These findings emphasize the need to standardize prognostic factors and improve CTCL treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406207PMC
http://dx.doi.org/10.4081/dr.2024.9970DOI Listing

Publication Analysis

Top Keywords

mycosis fungoides
8
fungoides sézary
8
sézary syndrome
8
early stages
8
stages disease
8
advanced stages
8
systemic treatments
4
treatments monoclonal
4
monoclonal antibodies
4
antibodies mycosis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!